Citigroup
BCRX icon

Citigroup’s BioCryst Pharmaceuticals BCRX Stock Holding History

Citigroup’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$950K Hold
95,000
– – ﹤0.01% 3483
2026
Q1 		$904K Buy
95,000
+94,800
+47,400% +$736K ﹤0.01% 3177
2025
Q4 		$1.56K Buy
+200
New +$1.45K ﹤0.01% 5492
2023
Q4 		– Sell
-39,900
Closed -$282K – 5701
2023
Q3 		$282K Hold
39,900
– – ﹤0.01% 3449
2023
Q2 		$281K Buy
+39,900
New +$320K ﹤0.01% 3711
2021
Q1 		– Sell
-19,700
Closed -$147K – 6272
2020
Q4 		$147K Buy
19,700
+16,700
+557% +$86.1K ﹤0.01% 5225
2020
Q3 		$10K Sell
3,000
-15,900
-84% -$68.1K ﹤0.01% 6598
2020
Q2 		$90K Buy
18,900
+7,600
+67% +$30.4K ﹤0.01% 5660
2020
Q1 		$23K Buy
11,300
+7,900
+232% +$21.8K ﹤0.01% 6594
2019
Q4 		$12K Buy
3,400
+800
+31% +$2.01K ﹤0.01% 7132
2019
Q3 		$7K Sell
2,600
-5,000
-66% -$15.6K ﹤0.01% 7204
2019
Q2 		$29K Buy
7,600
+1,300
+21% +$7.82K ﹤0.01% 6882
2019
Q1 		$51K Buy
6,300
+400
+7% +$3.42K ﹤0.01% 6320
2018
Q4 		$48K Buy
5,900
+400
+7% +$3.11K ﹤0.01% 6271
2018
Q3 		$42K Buy
5,500
+3,800
+224% +$25.5K ﹤0.01% 6657
2018
Q2 		$10K Sell
1,700
-1,200
-41% -$6.61K ﹤0.01% 7178
2018
Q1 		$14K Sell
2,900
-8,000
-73% -$41.1K ﹤0.01% 6904
2017
Q4 		$54K Sell
10,900
-1,400
-11% -$6.78K ﹤0.01% 6123
2017
Q3 		$64K Sell
12,300
-4,600
-27% -$23.6K ﹤0.01% 5858
2017
Q2 		$94K Buy
16,900
+10,300
+156% +$62.7K ﹤0.01% 5392
2017
Q1 		$55K Sell
6,600
-12,800
-66% -$89K ﹤0.01% 5622
2016
Q4 		$123K Buy
19,400
+18,800
+3,133% +$97.8K ﹤0.01% 5644
2016
Q3 		$3K Buy
+600
New +$2.4K ﹤0.01% 6860
2014
Q3 		– Sell
-1,800
Closed -$23K – 7056
2014
Q2 		$23K Buy
+1,800
New +$17.5K ﹤0.01% 5722

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Citigroup's BCRX Position: Q2 2026 in Review

Citigroup increased its BioCryst Pharmaceuticals (BCRX) stake by 406% in Q2 2026, buying an estimated $2.61M and bringing the position to 360,189 shares worth $3.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2427.

Citigroup first reported a position in BCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.6M in Q1 2024. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Citigroup held 360,189 shares of BioCryst Pharmaceuticals worth $3.6M as of Q2 2026.
  • Citigroup bought 289,025 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.61M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2427 holding.
  • Citigroup first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's BioCryst Pharmaceuticals position peaked at $11.6M in Q1 2024.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.